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Available online 29 September 2016Daptomycin (DAP) is a novel lipopeptide antibiotic which exhibits excellent antibacterial activity against most
clinically relevant Gram-positive bacteria, but the DAP-targeting protein molecules against host bacterial infec-
tion are far from clear. In order to discover bacterial protein response to DAP treatment, an iTRAQ-based quanti-
tative proteomic analysis was applied to identify differential bacterial proteome proﬁling of Staphylococcus
aureus (S. aureus) ATCC 25923 to 0.125 μg/ml DAP exposure. Totally 51 bacterial proteins were signiﬁcantly
changed with DAP treatment, among which 34 proteins were obviously up-regulated and 17 proteins were
down-regulated. Meanwhile, 139 bacterial cell membrane (CM) proteins were identiﬁed, and 7 CM proteins
were signiﬁcantly altered to decrease CM potential to disrupt bacterial cell membrane. Especially the up-regula-
tion of NDK and down-regulation of NT5 in several S. aureus strains are validated to be a universal variation ten-
dency response to DAP treatment. Under DAP exposure, bacterial membrane potential is decreased and cell
membrane is disrupted, and bacterial chromosome is aggregated, which contributes to bacterial DNA rapid re-
lease and induces bacteria death within 2–5 h. In general, multiple bacterial protein expressions are changed
in response to DAP antibiotic exposure, which disrupts host bacterial physiology by multiple cellular levels. To
our knowledge, this is the ﬁrst time to exactly identify infectious bacterial proteins in response to DAP antibiotic
action. Our ﬁndings help better understand DAP antibacterial mechanism and develop novel DAP derivatives
against the upcoming antibiotic-resistant bacterial infection.
Biological signiﬁcance:DAP is a novel lipopeptide antibiotic that it exhibits excellent in vitro activity against most
clinically relevant Gram-positive bacteria, and the investigations on its pharmaceutical action mode of DAP have
dramatically increased in the past decade due to its unique antimicrobial mechanism. However, the target mol-
ecules of DAP acting on the infectious bacteria, are far from clear. The state-of-the-art quantitative proteomic
technologies provide new avenues to uncover underlying mechanism of antibiotics. Our research main aims to
identify bacterial proteome proﬁling of host strain S. aureus response to DAP treatment through an iTRAQ-
based quantitative proteomic analysis, which contributes to understand DAP efﬁcient antibacterial activity and
the microbial-antibiotic interactions.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Daptomycin
Staphylococcus aureus
Antibacterial activity
Quantitative proteomic1. Introduction
Daptomycin (DAP), commercially also called Cubicinmade by Cubist
Pharmaceuticals, originally is approved for the treatment of bacteremia
and right-sided endocarditis caused by Staphylococcus aureus (S. aureus)
and methicillin-resistant S. aureus (MRSA) in 2003 [1,2]. DAP is a novel
lipopeptide antibiotic that displays rapid bactericidal activity in vitro
against most clinically relevant Gram-positive (G+) bacteria [1,2]. Byotherapy, West China Hospital,
ad, Chengdu 610041, PR China.
. This is an open access article undernow it exhibits excellent bactericidal activity against 6737 clinical G+
strains, and the minimal inhibitory concentration (MIC) of which is
ranged from 0.12 to 8 mg/l [3]. DAP also shows an activity against
multidrug-resistant G+ pathogens, including vancomycin-resistant
S. aureus [4–7].
As a highly efﬁcient antibacterial drug, the investigations on its phar-
maceutical action mode of DAP have dramatically increased in the past
decade. A widely accepted hypothesis of DAP antimicrobial activity is
that it inhibits the lipoteichoic acid biosynthesis of G+ pathogens to
dissipate bacterial cell membrane across the cytoplasmic membrane
[8,9]. Other studies indicate that DAP is a membrane-targeting antibiot-
ic, which binds to Ca2+ to form a micellar structure in solution andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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calcium ion [10]. And this oligomer contributes to delivering DAP to
cell membrane of S.aureus [11,12], which results in the dissipation of
cell membrane potential and potassium ion efﬂux, ultimately leads to
cell death [8,13]. However, the target molecules of DAP acting on the in-
fectious G+ bacteria, are far from clear.
At present, the state-of-the-art proteomic technologies provide new
avenues to uncover underlyingmechanism of antibiotics [14]. Microbial
proteomics has been developed greatly in revealing microbial pathoge-
nicity, metabolism, biomarker discovery, and drug mechanism [15,16].
For example, proteins from various S. aureus strains were analyzed
using one- or two-dimensional electrophoresis (2-DE) under different
conditions, and the protein alterations in microorganism allow for
understanding microbial cellular processes and particular functions
[17–19]. More importantly, the development of chromatographic sepa-
rations and MS–based quantitative proteomics, including the gel-free
approach, LC-MS/MS, isobaric tagging reagent for quantitative proteo-
mic analysis (iTRAQ) and the selected reactionmonitoring, has contrib-
uted to identiﬁcation of microbial pathogens [20] and bacterial proteins
response to drug treatment [21].
In this study, our research aims to identify cellular proteome proﬁl-
ing of S. aureus response to the antibiotic DAP treatment through an
iTRAQ-based quantitative proteomic approach, which enables us to fur-
ther discover the functional characterization of the infectious bacterial
proteins and the antibacterial molecular mechanism of DAP.
2. Materials and methods
2.1. Bacterial strains and growth conditions
The bacterial strains including S. aureus ATCC 25923, S. aureus CMCC
26003, S. aureus ATCC 6538 and methicillin sensitive S. aureus (MSSA),
were stored as a 20% glycerol stock at−80 °C until used. Each strain
was re-streaked from glycerol stocks to culture on Mueller-Hinton
agar, then was inoculated into 5 ml of Mueller Hinton broth (MHB) to
grow overnight at 37 °C with constant shaking.
For detection of bacterial growth response to the antibiotic treat-
ment, it is necessary to add ﬁnal concentration of 50 μg/ml Ca2+ and
10 μg/ml Mg2+ into MHB to exert DAP activity. Bacterial culture in
Ca2+,Mg2+ - containingMHBmediawas treatedwith different concen-
trations of DAP at 37 °C for 18 h with gentle shaking. And under the
same conditions with no DAP exposure, the mock of bacterial culture
was incubated with 1% DMSO as the negative control of antibiotic
treatment.
2.2. Minimal inhibitory concentration of DAP
The antibacterial activity of DAP towards S. aureuswas evaluated by
the broth micro-dilution assay [22]. DAP was serially diluted two folds
in culture in 96-well plates to obtain ﬁnal concentrations ranged from
0.0625 to 1 μg/ml. An equal volume of 10 μl culture, approximately con-
taining 5 × 105 cfu/ml S. aureus, was added to each well to incubate at
37 °C for 18 h, and the optical density at 600 nm (OD600nm) was mea-
sured. The minimal inhibitory concentration (MIC) was determined as
the lowest concentration which completely inhibited the bacterial
growth. MIC was measured by three different experiment repeats.
2.3. Time-kill kinetic analysis
In order to determine an optimal DAP treatment concentration for
the bacterial proteome identiﬁcation, a time-kill kinetic analysis [18],
was performed on S. aureus ATCC 25923. The bacteria were cultured
in MHB media respectively with 0.25MIC, 0.35MIC, 0.5MIC, MIC, 2MIC
of DAP exposure for 18 h, and each concentration of cultures was col-
lected to detect OD600nm for 3 times (n = 3). The DAP concentration,which exerts a 50–80% growth inhibition on bacteria at an exponential
growth phase, would be determined as the drug usage quantity.
2.4. Protein extraction
S. aureus ATCC25923 cells at an exponential growth phase were
cultured in MHB, containing 50 mg/l Ca2+ and 10 mg/l Mg2+ with
0.125 μg/ml DAP treatment. Bacterial cell pellets were collected by cen-
trifugation at 10,000 ×g at 4 °C for 20 min. To extract cellular proteins,
the harvested cells were washed twice with 0.9% (w/v) NaCl, and then
200 μl of 40 μg/ml lysostaphin (BBI, Markham, Canada) was added
followed by incubation on ice for 10min to remove cell walls. After cen-
trifugation with 3000 ×g for 1 min at 4 °C, cell precipitation was re-
solved in 200 μl extraction buffer (50 Mm Tris-HCl, pH 8.0, 0.2 mM
EDTA,100 mM NaCl, and 0.1% (v/v) Triton X-100). Proteins were ex-
tracted by sonication using a 950-Watt Ultrasonic processor (XINYI-
IID) at 30% amplitude for 15 min on ice, with pulse durations of 3 s on
and 9 s off. Then cellular debris was removed by centrifugation at
10,000 ×g for 30 min at 4 °C, and the supernatant was concentrated
by precipitationwith ice-cold acetone (1:6, v/v) at−20 °C for 4 h. Final-
ly, protein concentration was determined using the protein assay kit
(Bio-Rad, catalog No. 500-006) based on the Bradford method.
2.5. The iTRAQ labeling
A total of 120 μg of proteins per sample was used for each iTRAQ
labeling. Protein samples were reduced, cysteine blocked, digested
and labeled with respective isobaric tags using an iTRAQ® reagentMul-
tiplex kit (PN 4352135, AB Sciex, CA, USA) according to manufacturer's
protocols. To block cysteine residues, 20 μl dissolution buffer, 1 μl dena-
turant and 2 μl reducing reagentwere respectively added to each of two
sample tubes. The sampleswere incubated at 60 °C for 1 h, then 1 μl cys-
teine blocking reagent was added to incubate in the dark at room tem-
perature for 10min. For tryptic digestion, 10 μl of 1 μg/μl trypsin solution
(Trypsin Gold, Promega, Madison) were used to treat each of samples
overnight at 37 °C. The iTRAQ experiment was performed on two
groups. One group was the DAP-treated bacterial proteins with 114 la-
beling, and another group without drug treatment was the experimen-
tal control with 116 labeling. The two sampleswere individually labeled
with iTRAQ reagents 114,116 for 1 h at room temperature. The labeled
peptides from two groups were then equally mixed and dried using a
Speed Vac centrifuge (Thermo Electron Corporation, SPD131DDA, USA).
2.6. LC-MS/MS identiﬁcation
Peptidemixtures from two groups of labeled peptides were separat-
ed by using Easy nanoLC (Thermo Scientiﬁc, San Jose, CA) and MS
proﬁling spectra were obtained on a Q-Exactive mass spectrometer
(Thermo Scientiﬁc, San Jose, CA). The iTRAQ-labeled peptides were
loaded onto a trap column (2 cm× 100 μm, 5 μm, C18,Thermo scientiﬁc
column), and separated using a reverse-phase column (75 μ m ×
100 mm, 3 μm, C18, Thermo scientiﬁc) with a 220-min gradient at a
ﬂow rate of 250 nl/min. The mobile phase A was 0.1% formic acid in
LC/MS-grade water, and the mobile phase B was 0.1% formic acid in
84% acetonitrile. The peptides were separated with a linear gradient
0–35% B in 200min, 35%–100% B in 16min, and 100% B in 4min. Survey
scans were acquired over a mass range of 300 to 1800 at resolution of
70,000. For MS/MS analysis, the top10 intense ions were selected for
fragmentation by high energy collision dissociation (HCD) at normal-
ized energy of 30%. The MS/MS scans were acquired at resolution of
17,500. The MS identiﬁcation was performed in duplicate.
The collected rawdatawere processed using the ProteomeDiscover-
er software (version1.3, Thermo Scientiﬁc). The Mascot search engine
(v2.2, Matrix Sciences, London, UK) was utilized to search against the
UniProt database, Staphylococcus aureus species which contains
478,846 sequences (version 3.35, Jan 14th, 2013). The parameters for
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as 0.1 Da for MS/MS and 20 ppm for MS, (ii) trypsin enzyme speciﬁcity
and twomax-missed cleavages were allowed, (iii) the ﬁxedmodiﬁcation
included carbamidomethylation, iTRAQ8plex (N-term), iTRAQ8plex (K),
Oxidation (M) and iTRAQ8 plex (Y). In case multiple peptides were
identiﬁed for certain proteins, the peptide ratios were averaged to obtain
protein ratios.2.7. Real-time quantitative PCR
In order to detect the expression levels of genes, 1mgof bacterial cell
pellets obtained from 10ml of culture was treatedwith 200ml of 40 μg/
ml lysostaphin for 5 min at 37 °C, and the sample was performed to ex-
tract total RNAwith Trizol reagent (Life technology). The total RNAwas
resolved in nuclease-free water and stored at−80 °C for further use.
The reverse transcription reaction for cDNA (iScript cDNA synthesis
kit, Bio-Rad) was performed in 20 μl of reaction mixture including 1 μg
of total RNA as the templates, 4 μl of 5× iScript reaction buffer and 1 μl of
iScript reverse transcriptase. Real-time quantitative PCR (q-PCR) was
performed using the SYBR Green Supermix kit (Bio-Rad) on a Bio-Rad
CFX96 system according to the manufacturer’ instructions. All primers
for q-PCR were synthesized by Invitrogen Company in China. The PCR
primers for nucleoside diphosphate kinase (NDK) were (F) 5′-
AGAAAAGGACTAAAACTTGTCGGTG-3′ and (R) 5′-ACTGGTGCTGATG
TAATAAATGAAA-3′. Primers for (5′-nucleotidase) NT5 were (F) 5′-
GATAAGAGTAAAGAATCACGCAGACA-3′ and (R)5′-CTACCATACATTGG
GTTAGGGAAAA-3′. Primers for triosephosphate isomerase (TPI) were
(F) 5′-CGTTGTTATCGGTCATTCTG-3′and (R) 5′-TTTACCACTTTCACG
CTCTT-3′.The 16s rRNAof S. aureuswas taken as a control of comparison
in q-PCR, and its primers were designed (F) 5′-TACACACCGCCCGT
CACA-3′ and (R) 5′-CTTCGACGGCTAGCTCCTAAA-3′.
Each q-PCR reaction mixture (10 μl) was composed of 5 μl SYBR
Green supermix, 0.4 μl forward primer, 0.4 μl reverse primer, 3.2 μl
RNase-freewater, and 1 μl of the cDNA template. The reaction condition
was set as following procedures, including initial DNA denaturation for
3 min at 95 °C; 39 cycles of 30 s denaturation at 95 °C, 30 s annealing at
50 °C (forNDK), 59 °C (for NT5) or 55 °C (for TIP), then aﬁnal elongation
at 72 °C for 10min extension. Each gene expressionwasquantiﬁed byq-
PCR in a strain for three times (n= 3).Fig. 1. Growth curves of S. aureus ATCC 25923 against DAP treatment. Bacterial growth is
inhibited under MIC or 2MIC of DAP exposure for 2–18 h. While the bacterial growth,
under 0.25 MIC of DAP treatment, was similar with the normal culture. Each point
represented OD of bacteria measured by three different experiment repeats.2.8. Bacterial DNA quantiﬁcation
In order to detect bacterial DNA from died bacteria releasing into the
culture media, S. aureus was cultured in MHB with DAP exposure for
0.5 h, 1 h,2 h,3 h,5 h and 18 h respectively. Along with the bacterial
death response to DAP treatment, the bacterial DNA released into the
culture media, which was quantiﬁed with Quant-iT™ PicoGreen®
dsDNA Assay Kit (Life Technologies, USA). 1.5 × 108 cfu/ml bacteria, in-
cluding S. aureus ATCC 25923, S. aureus CMCC 26003, S. aureus ATCC
6538 and MSSA, were individually cultured in 5 ml of DAP-containing
MHB, and the concentration of DAP was depended upon the MIC for
each strain. Because the MIC of DAP against S. aureus ATCC 25923,
ATCC 6538 and MSSA was 0.25 μg/ml for 5 × 105 cfu/ml bacterial cells,
and totally 75 μg DAP was added to treat 1.5 × 108 cfu/ml bacteria to
detect the bacterial DNA content. Similarly, the DAP usage for 1.5 ×
108 cfu/ml S.aureus CMCC 26003 cells was determined as 18.75 μg.
The bacterial DNA in culture supernatant was collected by centrifu-
gation at 10,000 ×g for 3min. 100 μl of the diluted bacterial DNA sample
(a 10-fold dilution with TE buffer) wasmixed with 100 μl Picogreen re-
agent (1:200 diluted solution), and the mixture was added to each well
of a 96-well plate to incubate at room temperature for 5 min in dark.
Then the ﬂuorescence intensity at 480 nm excitation and 520 nm emis-
sionwas detected to calculateDNA contentwith a Varioskan Flash spec-
tral scan multimode plate reader (Thermo Fisher Scientiﬁc, USA).2.9. Transmission electron microscopy analysis
In order to observe bacterial morphology and ultrastructure alter-
ation under DAP treatment via a transmission electron microscopy
(TEM) analysis, totally 9 × 109 S. aureus ATCC 25923 were cultured in
60 ml MHB overnight with or without 75 μg DAP treatment, and cells
were harvested by centrifugation and washed with 0.1 M phosphate
buffer saline (PBS) for three times. Cell pellets with 2.5% glutaraldehyde
ﬁxativewere post-ﬁxed in 1%osmium tetraoxide and incubated at room
temperature for 1 h. After incubation, the sample was dehydrated with
graded ethanol-PBS solutions as 20% ethanol for 10min, 40% ethanol for
10min, 60% ethanol for 10min, 80% ethanol for 15min, 90% ethanol for
15min, and twice in 100% ethanol for 20min. The sampleswere ﬁxed in
epoxy resin and left to polymerize for 2 days. Each sample was cut into
approximately 90-nm thin slices, and lead citrate on grids. Morpholog-
ical and ultrastructural alterations of the bacteria were observed and
photographed by a TEM analysis with a ﬁeld-emission gun operating
at 200 kV (Tecnai G2 F20, FEI Company, USA).
2.10. Fluorimeter assay for bacterial membrane potential
Bacterial membrane potential of S. aureus, response to DAP expo-
sure, was measured by using a ﬂuorescent assay. S. aureus cells were
cultured with 0.5MIC of DAP treatment. 200 μl of S. aureus cell samples
was transferred into a 96-well plate, and a membrane potential sensi-
tive dye, 50 μM DiSC3 (3,3′-dipropylthiadicarbocyanine iodide; Life
technology), was added into each well to incubate for an additional
5 min at 37 °C. The ﬂuorescence intensity was detected on a Varioskan
Flash spectral scan multimode plate reader (Thermo Fisher Scientiﬁc,
USA), with an excitation wavelength of 622 nm and the ﬂuorescence
emission at 670 nm.
3. Results
3.1. Bacterial growth with DAP exposure
Firstly, the MIC of DAP against S. aureus was obtained. The MIC of
DAP towards S. aureusATCC 25923was 0.25 μg/ml. And theMIC against
other strains, including S. aureus CMCC 26003, S. aureus ATCC 6538 and
MSSA, was respectively 0.0625 μg/ml, 0.25 μg/ml and 0.25 μg/ml in turn.
Furthermore, the growth proﬁling of S. aureus ATCC 25923 response
to different concentration of DAP treatment was analyzed. In MHB
medium inoculated with 5 × 105 cfu/ml of S. aureus ATCC 25923, the
bacterial growth curves documented the inhibitory effect of DAP on
this strain. Bacterial growth was completely inhibited under either
0.25 μg/ml (MIC) or 0.5 μg/ml (2MIC) of DAP exposure for 2–18 h
(Fig. 1). And the bacteria growth was relatively inhibited by 60%
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niﬁcant difference between 0.25 MIC of DAP treatment and the control
samples. According to the time-kill kinetics on S. aureus ATCC 25923,
0.125 μg/ml, a half of MIC of DAP against this strain, was determined
as a sub-inhibitory concentration for analyzing bacterial proteome pro-
ﬁling response to DAP treatment.3.2. MS data analysis
The iTRAQ-based quantitative proteomic strategy, a relative and ab-
solute protein quantiﬁcation for multiple samples simultaneously [23],
was applied to analyze differential proteome expression of S. aureus
ATCC 25923 response to DAP treatment. This iTRAQ labeling method
of tracking relative concentrations of different proteins was used and
summarized in our previous reports [24,25]. The differential expression
levels (ratios) of proteins in DAP-treated bacteria versus the untreated
control were calculated based on the peak intensity iTRAQ-labelings in
MS/MS scans.
Overall, 872 proteins were conﬁdently identiﬁed at 1% or less false
discovery rate (FDR) among which 789 proteins derived from 4566
peptides were quantiﬁed. The iTRAQ ratios (treated/untreated) of 789
proteins nearly exhibited a normal distribution (Fig. 2A). The error fac-
tor (EF) and 95% conﬁdence interval (95% CI) and standard deviation
(SD) valueswere calculated based on peak ratios obtained fromall iden-
tiﬁed peptides. The average SD valuewas 0.30 for all 789 quantiﬁed pro-
teins, therefore a signiﬁcantly changed protein was deﬁned when the
changed ratio has at leastﬁve times of the average SD (SD). A differential
(changed) protein was simultaneously met the conditions of EF b 2,
change ratio N 5-fold of SD and student t-test at p-value b 0.05. More
specially, the differential proteins were included into the upregulated
proteins with expression level over 1.86-fold increase, and the down-
regulated ones with expression below 0.57-fold decrease. According toFig. 2.Proteome proﬁling identiﬁed in S. aureusATCC25923withDAP exposure. (A) Thepeak in
identiﬁed proteins exhibited a normal Gausses distribution. (B) Fifty-one bacterial proteins sign
over 1.86-fold (redpanes). (C) 51 differentially expressed proteinswere functionally sorted into
of the 51 altered proteins.these quantitative criteria, 51 proteins were found to have signiﬁcant
expression changes between the DAP-treated and the control group
(Table 1). Among these altered proteins, 34 proteins were increased
with ranging from1.86 to 9.85-fold, and three of themhave signiﬁcantly
high expression (N4.0-fold) after DAP treatment, whereas 17 proteins
were decreased with ranging from 1.77 to 3.68-fold.
3.3. Molecular functions of the altered proteins
The differentially expressed proteins were divided into several
groups based on the Gene Ontology (GO) molecular function analysis
(Table 1). For example, 23 proteins (45%) participate in catalytic
activity, and 9 proteins (18%) exhibit nucleotide binding activity.
Three (6%) proteins have a role in protein binding (including cofactor
binding and repressor protein), two proteins (4%) are considered to
have transporting function and one protein is related to toxin. In addi-
tion, 13 proteins (25%) were annotated as unknown functions (Fig. 2C).
The subcellular localization of the 51 changed proteinswere also cat-
egorized (Fig. 2D). Among them, 7 proteins locate in cell membrane, 19
proteins locate in cytoplasm (including one ribosomal protein) and two
proteins are mainly distributed in extracellular. The other 23 proteins
are unclear with exactly cellular localization.
3.4. Expression proﬁling of cell membrane proteins
Of all 789 quantiﬁed bacterial proteins, in total 139 cellular mem-
brane proteinswere identiﬁed, and 7 of themwere signiﬁcantly altered.
These 7 cell membrane (CM) proteins were classiﬁed into 2 groups ac-
cording to their contributions to the relative negative charge in mem-
brane surface (Table 2), which would be beneﬁcial to DAP binding and
the antibacterial action. Except to 2 increased proteins (succinate dehy-
drogenase cytochrome b-556 subunit and ATP synthase subunit A)with
a positive charge (pI N 7), the 5 proteins (nucleoside diphosphate kinasetensity ratios ofm/z=114 versusm/z=116 (treated vs. untreated) from789 quantitative
iﬁcantly altered, including 17 proteins down-regulated (green panes) and 34 up-regulated
6 functional categories according to the geneontology annotation. (D) Cellular localization
Table 1
Cluster analysis of the altered proteins.
Molecular function Accession number Protein name Fold changea pIb MW [kDa] Localizationc
Catalytic activity(23) 295127992 Succinate dehydrogenase cytochrome b-556 subunit 3.25 ± 0.22↑ 8.72 20.08 Membrane
282319755 AIR carboxylase 2.35 ± 0.11↑ 5.94 17.06
283471618 Nitrate reductase beta subunit 2.43 ± 0.37↑ 5.44 55.27
298695541 Inosine-uridine preferring nucleoside hydrolase 1.92 ± 0.22↑ 5.21 32.66 Cytoplasm
282320444 5′-nucleotidase 2.24 ± 0.07↓ 9.49 33.34
298695140 Regulatory protein RecX 2.67 ± 0.05↑ 5.85 29.05
257846453 Peptidase T 2.19 ± 0.01↑ 4.88 45.92
150373525 Molecular chaperone Hsp31 and glyoxalase 3 2.31 ± 0.19↑ 5.05 32.16
375034342 tRNA (5-methylaminomethyl-2-thiouridylate)-methyltransferase 1.94 ± 0.47↓ 5.82 36.55
253724222 Aspartate-semialdehyde dehydrogenase 1.93 ± 0.61↓ 5.08 36.26
257273054 D-lactate dehydrogenase 2.06 ± 0.16↓ 5.48 24.91
156721660 Orotidine 5′-phosphate decarboxylase 2.04 ± 0.01↑ 6.28 25.60
383357693 Pyruvate dehydrogenase E1 component alpha subunit 2.00 ± 0.41↑ 4.88 41.30
282320324 Dihydroneopterin aldolase 1.97 ± 0.33↑ 5.82 13.74
377697984 Alkyl hydroperoxide reductase subunit C 1.86 ± 0.27↑ 5.14 9.78
257847305 Acetyltransferase(S.aureus A9635) 1.87 ± 0.76↑ 4.67 19.88
257279654 Acetyltransferase(S.aureus 68–397) 2.19 ± 0.14↓ 5.16 19.95
365237094 N-acetylmuramoyl-L-alanine amidase Sle1 3.68 ± 0.69↓ 9.63 32.5 Extracellular
282331375 Glyceraldehyde-3-phosphate dehydrogenase type I 1.87 ± 0.64↓ 6.05 36.98 Unknown
253726636 Putative uncharacterized protein 1.77 ± 0.30↓ 10.05 10.29
257275550 6-phospho 3-hexuloisomerase 2.01 ± 0.37↑ 5.49 19.60
375018476 Hydrolase 1.89 ± 0.12↑ 5.33 28.86
282329413 ATP-binding protein involved in chromosome partitioning 1.77 ± 0.12↓ 5.31 38.38
Nucleotide binding(9) 365164976 Nucleoside diphosphate kinase 2.69 ± 0.17↑ 5.53 16.55 Membrane
257278840 Topoisomerase IV subunit A 1.86 ± 0.15↑ 6.42 90.99
344176905 HTH-type transcriptional regulator Sar 2.22 ± 0.10↑ 8.53 14.15 Cytoplasm
156722095 Holliday junction ATP-dependent DNA helicase RuvA 2.29 ± 0.51↑ 6.23 22.27
408428732 Similar to xylitol dehydrogenase 1.87 ± 0.22↓ 5.16 34.34
365245635 RNA pseudouridine synthase 2.02 ± 0.09↓ 7.64 21.59
253728322 DNA-dependent DNA polymerase family X 9.85 ± 0.78↑ 4.70 10.43 Unknown
377739719 Putative uncharacterized protein 2.57 ± 0.38↑ 5.88 10.54
7328270 hypothetical protein 2.54 ± 0.29↑ 5.96 31.04
Protein binding (3) 365243005 Ribosomal protein L7Ae 2.25 ± 0.31↑ 10.08 7.72 Cytoplasm; ribosome
282331292 Ribosomal silencing factor RsfS 1.92 ± 0.39↑ 4.79 13.44 Unknown
377749114 Immunoglobulin-binding protein sbi 2.11 ± 0.47↓ 9.32 49.2
Transporting (2) 377741740 ATP synthase subunit A 1.90 ± 0.32↑ 9.33 24.75 Membrane
375015204 Ferric iron reductase FhuF-like transporter 2.47 ± 0.34↑ 6.54 27.25
Toxin(1) 377709301 Gamma-hemolysin component B 2.06 ± 0.21↓ 8.29 25.9 Extracellular
Others(13) 374363031 hypothetical protein SAVC_04870 4.86 ± 0.55↑ 6.78 9.64 Unknown
320143212 Putative uncharacterized protein 6.70 ± 0.33↑ 5.01 6.63
371976235 PF03780 family protein 3.19 ± 0.27↑ 7.43 13.26
383359444 RecF/RecN/SMC N-terminal domain protein 2.27 ± 0.56↑ 5.38 47.05
365173901 Putative uncharacterized protein 2.20 ± 0.12↑ 3.75 7.97
365164517 MoaC domain protein 1.97 ± 0.10↑ 4.78 9.02
160367735 Putative uncharacterized protein 1.94 ± 0.15↑ 4.67 23.75
334275314 Putative uncharacterized protein 2.34 ± 0.09↑ 4.49 8.33
365225215 Putative 65 kDa membrane protein 1.95 ± 0.23↓ 9.86 41.97
374396522 Putative uncharacterized protein 2.33 ± 0.53↑ 4.56 9.73
377743258 Putative exported protein 2.56 ± 0.46↓ 6.62 5.67
253726412 Possible secretory antigen 2.09 ± 0.27↓ 9.54 12.75
334271011 Conserved domain protein 1.79 ± 0.38↓ 7.24 8.01
Notes: All quantitative data were recorded as mean ± SD (n = 2).
a The fold changes of differential proteins were calculated from 114/116 ratios, which should meet all parameters including p-value, fold-change and peak ratios.
b The isoelectric point of protein.
c The localization of proteins.
Table 2
Bacterial membrane proteins were altered with DAP treatment.
Chargea Accession number Protein name Change ratio pIb
Negative(−) 365164976 Nucleoside diphosphate kinase (NDK) 2.69 ± 0.17↑ 5.53
282319755 AIR carboxylase 2.35 ± 0.11↑ 5.94
283471618 Nitrate reductase beta subunit 2.43 ± 0.37↑ 5.44
375015204 Ferric iron reductase FhuF-like transporter 2.47 ± 0.34↑ 6.54
257278840 Topoisomerase IV subunit A 1.86 ± 0.15↑ 6.42
Positive(+) 295127992 Succinate dehydrogenase cytochrome b-556 subunit 3.25 ± 0.22↑ 8.72
377741740 ATP synthase subunit A 1.90 ± 0.32↑ 9.33
The experiment was performed in duplicate (n = 3).
a Protein shown a negative charge when the pI b 7 in neutral pH solution, while shown a positive charge when the pI N 7.
b The isoelectric point of protein.
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247W. Ma et al. / Journal of Proteomics 150 (2017) 242–251(NDK), topoisomerase IV subunit A, AIR carboxylase, nitrate reductase
beta subunit, ferric iron reductase FhuF-like transporter and topoisom-
erase IV subunit A) show negative charges (pI b 7) responsive to DAP
treatment, which helps to form relatively negative surface charges. Re-
garding biological functions of 7 CM proteins, the up-regulated protein
NDK is a major enzyme in nucleoside triphosphate synthesis [26,27].
Other four proteins, succinate dehydrogenase cytochrome b-556 sub-
unit, AIR carboxylase, nitrate reductase beta subunit and ATP synthase
subunit A participate in enzyme catalytic activity. Topoisomerase IV
subunit A is concerned with nucleotide binding. The expression levels
of CM proteins have inﬂuences on bacterial cell surface charges, which
induces DAP to disturb membrane integrity and further disrupts nucle-
otide acid metabolism. Our proteome data supports previous hypothe-
sis on a membrane-based mode of DAP action [28].3.5. Expression change of NDK and NT5 with DAP exposure
We noticed that NDK and NT5 are two important enzymes for cellu-
lar nucleotide acid metabolism. The up-regulated protein NDK is a
major enzyme in nucleoside triphosphate synthesis [26,27], and the de-
creased protein NT5 is a bacterial enzymewhich speciﬁcally hydrolyzes
5′-nucleotides to release phosphoric acid [29,30]. Therefore the expres-
sion change of NDK and NT5 with DAP exposure was further validated
in more different S. aureus strains.Fig. 3. Representative MS/MS spectra of NDK and NT5 to quantify protein expression levels. Th
tagged with iTRAQ reagent 114. (A) The MS/MS spectra of one peptide with m/z 2198.49 of
sequence as LMQVPMELAETHYGEHQGK. The local zoom spectra was shown and the peak in
peptide LMQVPMELAETHYGEHQGK of NDK, shown NDK was up-regulated. (B) The MS/MS s
MS spectra readily assign the amino acid sequence as SSAEVQQTQQASIPASQK. The local zoom
87 = 0.39). (C) The MS/MS spectra of one peptide with m/z 1130.25 of TPI were show
AVAGLSEDQLK. The local zoom spectra was shown and the peak intensity ratio of m/z114.11
TPI, were almost identical in MS.Based on the isotope peak ratio of tag 114 versus tag 116 in MS, the
protein NDKwas averagely increased by 2.95 folds under DAP exposure.
One representative peptide (LMQVPMELAETHYGEHQGK) of NDK was
taken to quantify its expression level (Fig. 3A). The peak intensity
ratio of isotope labeled peptides with iTRAQ tag 114 versus 116 was
3.50, which showed that the expression level of NDK was increased by
3.50-fold with the drug treatment. Similarly, NT5 was quantiﬁed to
2.24-fold down-regulation averagely from the two isotope peptide
ratios (Table 3). For example, a peptide (SSAEVQQTQQASIPASQK) of
NT5 with isotope peak ratio (m/z 114 versus 116) was 0.39
(34counts/78counts), which indicated that the NT5 expression was de-
creased by 2.56-fold by drug exposure (Fig. 3B).Meanwhile, the TPI, one
housekeeping gene in Staphylococci [31], was no change (average
change ratio was 1.00 ± 0.21) with drug treatment, which was taken
as a comparison control for MS quantiﬁcation. And an isotope peak in-
tensity ratio of m/z114 versus m/z 116 from a peptide AVAGLSEDQLK
of TPI were exampled to show almost identical (100counts/92counts=
1.09) in MS (Fig. 3C).
In order to detect the gene expression level of NDK and NT5 for DAP
exposure, several S. aureus strains including S. aureus ATCC 25923, S. au-
reusCMCC 26003, S. aureusATCC 6538 andMSSAwere further validated
to gene expression by q-PCR. Under the condition of 0.5MIC of DAP
treatment, the gene expression of NDK in these strainswas respectively
increased by 2.75, 2.20, 3.17 and 1.91 fold (p b 0.05) (Fig. 4A),while NT5
genewas signiﬁcantly decreased by 2.43, 2.02, 4.28 and 1.94 fold in turne control sample was labeling with iTRAQ reagent 116, and the DAP–treated sample was
NDK were shown. The y-ion series in the MS/MS spectra readily assign the amino acid
tensity ratio of m/z114.11 versus m/z 116.11 (98/28 = 3.50), from an isotope labeling
pectra of one peptide with m/z 1888.01 of NT5 were shown. The b-ion series in the MS/
spectra was shown and the peak intensity of m/z114.11 was lower than m/z 116.11 (34/
n. The y-ion series in the MS/MS spectra readily assign the amino acid sequence as
versus m/z 116.11 (100/92 = 1.09), from an isotope labeling peptide AVAGLSEDQLK of
Table 3
The isotope peptides of NDK and NT5 were identiﬁed by iTRAQ (n = 2).
Protein name Peptide sequencea Ion scoreb Peptide ratio (114/116)c Average protein ratio (114/116)d Protein change-folde
NDK LMQVPMELAETHYGEHQGK 66.84 3.50 2.69 ± 0.17↑ 2.95 ± 0.15↑
NIIHGSDSLK 16.96 1.88
NT5 SSAEVQQTQQASIPASQK 81.51 0.390 0.445 ± 0.07 2.24 ± 0.33↓
ALYLQGYNSAK 49.01 0.553
QQGIPQAK 36.11 0.470
AkPVYGAK 19.43 0.422
TPI QTIADLSSK 42.24 0.94 1.003 ± 0.192 1.00 ± 0.21
ANDVVGEQVK 33.15 1.18
AVAGLSEDQLK 20.91 0.76
APIIAGNWK 34.11 1.13
a Unique peptides with iTRAQ tag labeling used for MS quantiﬁcation.
b Probability-based Mascot scores.
c The peak intensity ratio was the DAP-treated sample with tag 114 versus the control with tag116 (114/116).
d The average peak ratio (114/116) of a protein. At least one peptide was used for quantiﬁcation, and it was averaged when several peptides were used to quantify a protein.
e The change-fold of a protein, calculated from 114/116 ratio or its reciprocal (n = 2).
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MS quantiﬁcation in protein level. Therefore, the up-regulation of NDK
and down-regulation of NT5 in S. aureus strains are a universal variation
tendency response to DAP treatment.
3.6. DAP reduces cell membrane potential
Due to CM proteinswith different charges, we evaluated DAP effects
on cell membrane depolarization and potential loss in four S. aureus
strains under conditions of at one-half the DAP MIC, which was used
as the sub-inhibitory concentration for our proteomic analysis. The ﬂuo-
rescence of membrane potential-sensitive ﬂuorescent probe DiSC3 will
decrease due to ﬂuorescence dequenching when the dye partitions to
the surface of polarized cells and the membrane potential is disrupted.
Thereby, the depolarized cells produce higher signal than the control
[32]. As shown in Fig. 5, cell ﬂuorescence intensities were greatly in-
creased for each stain when a half of MIC was respectively treated to
S. aureus ATCC 25923, S. aureus ATCC 6538, MSSA (0.125 μg/ml DAP)
and S. aureus CMCC 26003 (0.03125 μg/ml DAP) for 5 h (p b 0.01),
which demonstrated bacterial membrane potential was greatly dissi-
pated and membrane depolarization was caused. The biological effects
on bacterial membrane potential are partly responsible for DAP antimi-
crobial activity [33].
3.7. DAP induces bacterial DNA rapid release
Furthermore, bacterial cell membrane morphology changes respon-
sive to DAP treatment were observed by TEM. Bacterial cell membrane
morphology and cell ultrastructure of S. aureus ATCC 25923 under 1Fig. 4. Expression levels of NDK and NT5 in different S. aureus strains with DAP exposure. S.
expression level of NDK and NT5 under 0.5MIC of DAP exposure. Each gene expression was
increased by 2.75, 2.20, 3.17 and 1.91 fold on average (p b 0.05) in S. aureus ATCC 25923,
decreased by 2.43, 2.02, 4.28 and 1.94 fold (p b 0.05) respectively.MICof DAP (0.25 μg/ml) exposure overnightwere both obviously differ-
ent from the mock strain with no drug treatment (Fig. 6). Compared
with the untreated strain (Fig. 6B, D), bacterial CM was disrupted and
damagedwith nomembrane integrity (Fig. 6A), aswell as the antibiotic
caused bacterial chromosome aggregation (Fig. 6C), which were typical
features that DAP exhibited antimicrobial effects on S. aureus to induce a
quick release of bacterial DNA into cultured media (Fig. 7A).
According to the biological effects of DAP on bacterial cellmembrane
potential and nucleotide metabolism, we further quantitatively detect-
ed the amount of bacterial DNA release after DAP treatment. For S. aure-
us ATCC 25923, CMCC 26003, ATCC 6538 and MSSA, a quickly sudden
release of bacterial DNA at a different time-point for DAP treatment 1–
3 h, demonstrated that DAP has approached its maximum antibacterial
activity for each strain (Fig. 7). For example, the amount of bacterial
DNA release by DAP treatment for 3 h, 64.9 ng/ml, was 7.5-time higher
than that for 2 h, 8.6 ng/ml in S. aureus ATCC 25923 (Fig. 7A). The re-
leased DNA for S. aureus CMCC 26003 was increased by 3.7-fold, from
41.8 ng/ml at DAP exposure time point 0.5 h to 156.9 ng/ml at drug
treatment time point 1 h (Fig. 7B), and 21.2 ng/ml bacterial DNA at
treat time point 0.5 h, was greatly increased to 4.7-fold, containing
99.7 ng/ml at drug treatment time point 1 h for S. aureus ATCC 6538
(Fig. 7D). However, a relatively gradual release of bacterial DNAwas ob-
served in MSSA (Fig. 7C), the amount of DNA release was signiﬁcantly
increased upon DAP treatment within 5 h, from14.9, 31.4, 42.8, 105.1
to 132.3 ng/ml at time point 0.5 h, 1 h, 2 h, 3 h and 5 h.
Generally DAP quickly promotes bacterial DNA release and leads to
bacteria death within 2-5 h. For S. aureus ATCC 25923 and MSSA, the
amount of bacterial DNA in culture supernatant was 81.2 ng/ml and
132.3 ng/ml respectively after DAP treatment for 5 h, which was almostaureus ATCC 25923, CMCC 26003, ATCC 6538 and MSSA were selected to determine the
quantiﬁed by q-PCR in a strain for three times (n = 3). (A) The expression of NDK was
CMCC 26003, ATCC 6538 and MSSA respectively. (B) The expression of NT5 gene was
Fig. 5.DAP reduces bacterial membrane potential measured by ﬂuorimetry assay (n= 3).
S. aureus cultures, including S. aureus ATCC 25923, CMCC 26003, ATCC 6538 and MSSA,
were incubated with or without a one-half MIC of DAP for 5 h to detect membrane
potential respectively with 3 times (n = 3). The increase of ﬂuorescence intensity
means reductions of bacterial membrane potential.
249W. Ma et al. / Journal of Proteomics 150 (2017) 242–251equal with that with DAP exposure for 18 h (83.9 ng/ml and 136.2 ng/
ml). At the drug action for 2 h, the amount of released DNA from S. au-
reus CMCC 26003 and ATCC 6538, 185.5 ng/ml and 152.4 ng/ml in turn,
was similar with 191.3 ng/ml and 154.3 ng/ml after DAP treatment for
5 h, and this indicated the two S. aureus strains were almost killed
after 2 h of antibiotic action.
4. Discussion
The proteomics tool enlarges our understanding for microbial be-
haviors upon different stimuli or environmental conditions. Although
previous studies show the mode of action of DAP is different from any
other known antibiotics, its exact antibacterial mechanism remains to
be determined. Our proteomic data indicated that DAP at a half concen-
tration of MIC would affect the expression levels of many functional
bacterial proteins of host strain S. aureus ATCC25923, including some
CM proteins. Especially these altered CM proteins confer upon theirFig. 6. Bacterial cell membrane and cell ultrastructure are obviously changed with DAP
treatment. The S. aureus ATCC 25923 bacteria were incubated overnight with a MIC of
DAP treatment (A, C) and no drug usage (B, D). (A) The damaged cell membrane was
shown in arrows. (C) The clumps or aggregation of bacterial chromosome were
indicated in arrows. While regular cell ultrastructures were visible with no antibiotic
treatment on S. aureus ATCC 25923 cells (B, D). Scale bar represented 0.5 μm (A) and
0.2 μm (B, C, D), respectively.contributions for DAP binding directly or indirectly with bacterialmem-
brane to exert antibacterial activity due to the enrichment of negative
charge in bacterial CM surface. To our best knowledge, the present
proteomic study is the ﬁrst report to reveal the global changes of path-
ogenic bacteria proteins with DAP treatment, which helps us under-
stand its acting molecules and develop novel DAP derivatives against
conventional antibiotic-resistant bacterial infection. Of course current
proteomic strategy has been widely applied for different microbial or
antimicrobial proteome proﬁling. For example, a bacteriocin (nisin) in
food poisoning has been identiﬁed to affect bacterial proteins associated
to oxidative stress by a comparative proteomic study [34].
Moreover, two signiﬁcantly altered proteins, NDK andNT5,were no-
ticed their functional roles in bacterial nucleotide acid metabolism.
Structurally, NDK was negative in charge (pI b 7) with 2.95-fold upreg-
ulation while NT5was positively charged (pI N 7) with 2.24-fold down-
regulation. Functionally, both of the two molecules were important
enzymes correlated with purine metabolism. Based on the data set,
we have demonstrated that the cooperative effects of DAP on CM dam-
age and DNA release in S. aureus (Figs. 6 and 7). Therefore DAP not only
acts on bacterial CM proteins to result in the decrease of membrane po-
tential and depolarization, it but also affects bacterial DNA metabolism,
accompanied with bacterial DNA efﬂux, to exert antibacterial activity.
This double antibacterial pathways confer DAP with a broad spectrum
and excellent bactericidal activity for serious bacterial infections even
caused by MRSA and vancomycin-resistant S. aureus.
S. aureus is a human pathogen causing a wide variety of diseases
ranging fromwound infection to endocarditis, osteomyelitis, and sepsis
[35]. Due to its ubiquity and its ability to survive in the terrestrial envi-
ronment, it remains amajor threat to human health in the hospitals and
also in the community. S. aureus has become increasingly problematic in
the past decades. Although DAP is a novel cyclic lipopeptide antibiotic
displays rapid bactericidal activity against S. aureus, recently DAP-resis-
tant pathogen is an increasing challenge in treating infections. Some
clinical cases of DAP-resistance or the decreased susceptibility to DAP
have been reported [36,37]. Some genetic changes may correlate with
reduced susceptibility of DAP [38]. So far, this study has discovered
the effects of DAP on S. aureus proteins by proteomics analysis, which
greatly helps to completely understand microbial-antibiotic interac-
tions and DAP antibacterial target proteins, as well as develop more ef-
ﬁcient DAP-based derivatives with an altered pharmaceutical spectrum
to address upcoming antibiotic-resistant pathogens.
Our quantitative proteomic analysis revealed 51 bacterial proteins,
34 up-regulated and 17 down-regulated, were signiﬁcantly changed
responsive to DAP exposure at sub-inhibitory concentration. The
differentially expressed bacterial proteins involve in multiple biological
functions including catalytic activity, nucleotide binding, protein bind-
ing and other biological activities. On the other hand, totally 139 identi-
ﬁed strain proteins locate in bacterial cell membrane, 7 CM proteins
were signiﬁcantly altered in expression level which reduced bacterial
membrane potential to help DAP disrupt bacterial CM to perform anti-
bacterial activity. Moreover, the morphological and ultrastructural al-
terations of DAP-treated S. aureus ATCC 25923 via TEM observations
clearly demonstrated bacterial cell membrane was disrupted and dam-
aged with no membrane integrity, and bacterial chromosome was ag-
gregated, which resulted in bacterial DNA rapid release and induced
bacteria death quickly.
Especially two important bacterial nucleotide acidmetabolism asso-
ciated proteins [26–29], the up-regulation of NDK (nucleoside-diphos-
phate kinase) based on GenPept accession no. WP_000442484 and
down-regulation of NT5(5′-nucleotidase) based on GenPept accession
no.WP_001033881 are validated to be a universal variation tendency
responsive to DAP treatment in several S. aureus strains. NDK and NT5
both take part in purine metabolism in other reports, including
deoxyguanosine (Fig. 3A in Ref. [39]) and deoxyadenosine synthesis
(Fig. 3B in Ref. [39]). The NDK is located on CM and it exhibits a major
role in the synthesis of nucleoside triphosphates (NTPs) or the deoxy
Fig. 7. DAP rapidly induces bacterial DNA release. 7.5 × 108 bacterial cells respectively from S. aureus ATCC 25923, CMCC 26003, MSSA and ATCC 6538 were treated with 1 MIC of DAP
treatment for overnights (n = 3). (A) The amount of DNA release from treated S. aureus ATCC 25923 was 5.2, 6.6, 8.6, 64.9, 81.2 and 83.9 ng/ml at the time point of 0.5, 1, 2, 3, 5 and
18 h. Similarly, the released DNA from S. aureus CMCC 26003 was 41.8, 156.9, 185.5, 193.6, 191.3 and 173.5 ng/ml in turn under drug treatment for 0.5, 1, 2, 3, 5 and 18 h (B). And at
the same conditions, DNA release from treated MSSA strain was 14.9, 31.4, 42.8, 105.1, 132.3, 136.2 ng/ml (C), while there was 21.2, 99.7, 152.4, 60.9, 154.3, 144.9 ng/ml DNA detected
from S. aureus ATCC 6538 (D).
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transduction and pathogenicity [27]. The ATP gamma phosphate is
transferred to the NDP beta phosphate via a ping-pong mechanism
[40], using a phosphorylated active-site intermediate. Meanwhile, NT5
is associated with the adenosine synthesis in S. aureus [26,41]. NT5 is a
hydrolase acting on ester bonds, it is a bacterial membrane-bound
enzyme which speciﬁcally hydrolyzes 5′ position of nucleoside
monophosphate thus rapidly regenerates phosphoric acid [28]. ATP-de-
pendent intracellular proteolysis plays an important role in cellular
physiology of bacteria [42,43]. Therefore, the increased expression of
NDK promotes phosphoric acid consumption and dNTP accumulation,
while the decreased expression of NT5 inhibits dephosphorylation. In
bacteria, DNA recycling needs several specialized catabolic enzymes
including the NT5 and NDK. The two enzymes involve in the de novo
synthesis of purines in growing bacterial cells, the antibiotic DAP affects
CM charges and brings about their abnormal levels to disrupt bacterial
purine metabolism balance, which is at least partially responsible for
DAP antibacterial activity.
Proteins interacting with NDK (Fig. 1 in Ref. [39]) and NT5 (Fig. 2 in
Ref. [39]) are also tightly linked with the nucleotide acid metabolism
pathway, based on a biological network analysis using an online soft-
ware STRING (http://string-db.org). NDK lies in the central position to
interact with several kinase proteins for nucleotide acid metabolism.
For example, guanylate kinase (GMK) is an essential kinase for recycling
GMP and cGMP. Adenylate kinase (ADK) is a small ubiquitous enzyme
for cell growth. And thymidylate kinase (TMK) is an essential kinase
for phosphorylation of dTMP to form dTDP in both de novo and salvage
pathways. The other molecule NT5 is linked together with ATP-binding
protein and other several uncharacterized proteins. Generally, bacterial
intracellular nucleotide metabolism is achieved through coordinating
with regulation of those kinase proteins. Of course, we will focus on
the association of DAP with these two proteins in bacterial nucleotide
acid metabolism in future study.5. Conclusion
Our quantitative proteomic analysis revealed 51 bacterial proteins,
including 34 up-regulated and 17 down-regulated, were signiﬁcantly
changed in response to DAP exposure at sub-inhibitory concentration.
The differentially expressed bacterial proteins involve in multiple bio-
logical functions including catalytic activity, nucleotide binding, protein
binding and other biological activities. On the other hand, totally 139
identiﬁed strain proteins locate in bacterial cell membrane, 7 CM pro-
teinswere signiﬁcantly altered in expression levelwhich reduced bacte-
rial membrane potential to help DAP insertion into bacterial CM to
perform antibacterial activity. Especially two important bacterial nucle-
otide acid metabolism associated proteins, the up-regulation of NDK
and down-regulation of NT5, are validated to be a universal variation
tendency against DAP treatment in several S. aureus strains. Further-
more, the morphological and ultrastructural alterations of DAP-treated
S. aureusATCC 25923 via TEM observations clearly demonstrated bacte-
rial cell membrane was disrupted and damaged with no membrane in-
tegrity, and bacterial chromosome was aggregated, which resulted in
bacterial DNA rapid release and induced bacteria death quickly. The
quantitative bacterial proteomic analysis revealed DAP bactericidal
targeting host proteins as a high effective antimicrobial antibiotic.
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